TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy females~Exclusion Criteria:~* no ocular diseases

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Open label (Type: EXPERIMENTAL): Each participant will be treated with three 3900 mg doses of calcium formate on each study day (i.e., days 1-14).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotics (Bio-Three) in Children's Enterocolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical symptom of diarrhea less than 3 days~Exclusion Criteria:~* Severe abdominal distension with risk of bowel perforation~* Risk for sepsis~* Past history with surgical operation of gastrointestinal tracts

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adolescents 12-21 years of age with type 1 diabetes (defined as having positive antibodies as well as insulin requirement)~2. Willing to consent for participation in study~3. Body Mass Index (BMI) \>5% on growth charts~Exclusion Criteria:~1. Current use of medications known to affect insulin sensitivity: oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, metformin or thiazolidinediones.~2. Currently pregnant or breastfeeding women~3. Use of a thiazolidinedione within 12 weeks~4. Severe illness or Diabetic Ketoacidosis within 60 days~5. Macroalbuminuria~6. Hemoglobin A1c \> 12%~7. Weight \> 136.4 kg or \< 42 kg, BMI \< 5%~8. Creatinine \> 1.2~9. Hemoglobin \< 9~10. Major psychiatric or developmental disorder limiting informed consent~11. Implanted metal devices~12. Inability to tolerate ≥500mg twice a day of metformin

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women whose last menstruation was at least two years previously

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age or older.~* Patients who were diagnosed as moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization.~Exclusion Criteria:~* Known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam sodium, other penicillins, or cephems.~* Hepatic dysfunction \[Aspartate Aminotransferase(AST), Alanine Aminotransferase (ALT), total bilirubin \> 3 times upper limit of normal range values\].~* Severe renal dysfunction (creatinine clearance \< 30 ml/min).~* Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- ampicillin sodium/sulbactam sodium (Type: EXPERIMENTAL): ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the BEL113750 Protocol in Northeast Asia through Week 48 OR have completed the open-label extension of C1115 in Japan.~* Be able to receive the first dose of belimumab for BEL114333 four weeks (minimum of 2 weeks, maximum of 8 weeks) after the last dose in BEL113750 OR be able to receive the first dose of IV belimumab 1 week (plus a 1 week visit window) after the last dose of open-label SC belimumab in C1115..~Exclusion Criteria:~* Have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases), or experienced an adverse event (AE) in the Phase 3 study that could, in the opinion of the principal investigator, put the subject at undue risk.~* Have developed any other medical diseases (e.g., cardiopulmonary), laboratory abnormalities, or conditions (e.g., poor venous access) that in the opinion of the principal investigator, makes the subject unstable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label Belimumab (Type: EXPERIMENTAL): Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with typical Parkinson's disease according to the Gibb criteria and the Parkinson's Disease Society criteria (Daniel and Lees, 1993).~* Ideally less than 2 to 3 years since disease onset and never more than 4 years.~* Patients on dopaminergic drugs and/or L-Dopa.~* Non-fluctuating disease because otherwise the degenerative process would be well advanced, the clinical score would vary from one day to another and the imaging evaluation would be complicated by dyskinesia.~Exclusion Criteria:~* Subjects over the age of 80~* Demented subjects: MMSE score ≤ 24, Mattis score of \< 130 and DSM IV criteria~* Subjects with radiological anomalies on MRI, whether incidental or suggestive of vascular involvement or significant cortical or subcortical atrophy~* Subjects for whom MRI is contra-indicated (metal objects in the body, severe claustrophobia, pacemaker, etc.)~* Subjects undergoing brain stimulation~* Very severe rest tremor, which could induce MRI artifacts~* Subjects that have not stabilized in terms of the therapeutic regimen and who are likely to require changes in their dopamine therapy in the coming 6 months~* Hoehn and Yahr stage ≥ 3 in the Off state, indicating the need for walking assistance in the absence of treatment.~* Hypersensitivity to iron chelator drugs~* Patients at risk of or having experienced agranulocytosis~* Patients on a drug that can potentially induce agranulocytosis (clozapine, Closaril®/Leponex®)~* Patients with anemia (regardless of the latter's etiology) or a history of other hematological diseases - even an iron deficiency~* Ferritin blood level \< 100 ng/ml (100 µg/l)~* A history of hemochromatosis or known iron metabolism disorders.~* Pregnant or breastfeeding women or women not taking effective contraception~* Kidney or liver failure~* Blood coagulation disorders, antiplatelet drugs or anticoagulants~* Concomitant treatment with aluminum-based antacids (interaction)~* Concomitant treatment with vitamin C (interaction)~* Presence of other serious diseases~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- deferiprone (Type: ACTIVE_COMPARATOR): deferiprone 30 mg/kg/day
- placebo (Type: PLACEBO_COMPARATOR): placebo : 30 mg/kg/day, in 2 liquid doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* outpatient colonoscopy for screening for other Gi related problems~Exclusion Criteria:~* Severe Congestive Heart Failure (CHF),~* Chronic Kidney Disease (CKD),~* less than age 18 or more than 80 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- miralax (Type: EXPERIMENTAL): miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
- moviprep split dose (Type: EXPERIMENTAL): Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
- Subjects who suffer from tooth sensitivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Dentifrice containing stannous fluoride
- Arm 2 (Type: ACTIVE_COMPARATOR): Marketed dentifrice containing Sodium Monofluorophosphate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Loss in Women With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Anorexia Nervosa,~* Over 18,~* Female,~* Decreased bone density~Exclusion Criteria:~* Medications to increase bone density

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Placebo Actonel (risedronate) and active testosterone patch
- 3 (Type: ACTIVE_COMPARATOR): Active Actonel (risedronate) and active testosterone patch
- 4 (Type: ACTIVE_COMPARATOR): Active Actonel (risedronate) and placebo testosterone
- 1 (Type: PLACEBO_COMPARATOR): Placebo testosterone patch and placebo Actonel (risedronate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Participants must be in good general health, in the opinion of the investigator, with no clinically significant deviation from normal in medical history, physical examination findings, ECGs, or laboratory results.~* Participants must have a BMI of 30 kg/m2 to 40 kg/m2 inclusive~* Women (not of childbearing potential) and men aged 18 to 60 years, inclusive~Exclusion Criteria:~* Previous participation in the current study~* Inability or unwillingness to comply with protocol-defined restrictions or requirements regarding lifestyle, diet, concomitant medications, or other aspects of the study~* Inability to tolerate the oLTT meal or to comply with oLTT testing conditions~* Inability to tolerate oral medication~* Inability to tolerate venipuncture and/or inadequate venous access~* Women who are breastfeeding~* Medical Conditions~* History of lactose intolerance~* Any significant (in the opinion of the investigator) acute or chronic illness~* Type 1 or 2 diabetes~* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population~* Previous/Concomitant Therapy~* Previous exposure to BMS-963272~Other protocol-defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- BMS-963272 or Placebo once daily (QD) (Type: EXPERIMENTAL): None
- BMS-963272 or Placebo every 12 hours (Q12H) (Type: EXPERIMENTAL): None
- BMS-963272 or Placebo every 8 hours (Q8H) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for Bipolar I Disorder, Most Recent Episode Manic or Mixed~* hospitalized voluntarily at study initiation for treatment of manic episode~* history (prior to study initiation) of at least one documented manic or mixed episode that required treatment~* total score \>=20 on the Young Mania Rating Scale (YMRS) at start of the study~Exclusion Criteria:~* Meets DSM-IV criteria for Schizoaffective Disorder or for rapid cycling~* borderline or antisocial personality disorder~* history of substance dependence (excluding nicotine and caffeine) within the 3 months prior to study initiation~* seizure disorder~* females who are pregnant or nursing, or those lacking adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed.~* Male and female patients ≥ 18 years of age.~* Diagnosis of HS ≥ 1 year prior to baseline.~* Patients with moderate to severe HS defined as:~* A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules AND~* Inflammatory lesions should affect at least 2 distinct anatomic areas~* Patients agree to daily use of topical over-the-counter antiseptics on the areas affected by HS lesions while on study treatment.~Exclusion Criteria:~* Total fistulae count ≥ 20 at baseline.~* Any other active skin disease or condition that may interfere with assessment of HS.~* Active ongoing inflammatory diseases other than HS that require treatment with prohibited medications.~* Use or planned use of prohibited treatment. Washout periods detailed in the protocol have to be adhered to.~* History of hypersensitivity to any of the study drug constituents.~* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- secukinumab 1 (Type: ACTIVE_COMPARATOR): Secukinumab 300mg every 2 weeks
- secukinumab 2 (Type: ACTIVE_COMPARATOR): Secukinumab 300mg every 4 weeks
- placebo 1 (Type: PLACEBO_COMPARATOR): Placebo group to secukinumab 300mg every 2 weeks
- placebo 2 (Type: PLACEBO_COMPARATOR): Placebo group to secukinumab 300mg every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female,between 35 and 85 years of age~2. Indicated for Total hip replacement for various hip diseases~3. Has preoperative DXA study within 3 months before the total hip replacement procedure or willing to receive preoperative DXA study as a baseline comparison~4. Signed written informed consent~5. Standard transgluteal approach for total hip replacement using Zimmer Triology Cup and Versys Fiber Metal Taper Stem with metal to highly cross-linked polyethylene bearing surface~Exclusion Criteria:~1. Any prior use of intravenous bisphosphonate within the last 2 years~2. Uncontrolled seizure disorders associated with falls~3. A history of invasive malignancy of any organ system, treated or untreated, within the past five years; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed~4. Carcinoma in situ of the uterine cervix~5. History of osteogenesis imperfecta, multiple myeloma, or Paget's disease~6. Active primary hyperparathyroidism~7. History of iritis or uveitis~8. Self-reported history of diabetic nephropathy or retinopathy~9. AST or ALT more than twice the upper limit of normal~10. Alkaline phosphatase more than twice the upper limit of normal~11. Serum calcium 2.75 mmol/L (11.0 mg/dL)~12. Baseline renal insufficiency (calculated creatinine clearance 35 ml/min)~13. History of hypersensitivity to bisphosphonates~14. Use of any investigational drug(s) and/or devices within 30 days prior to randomization~15. Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the participant from adhering to the Protocol or completing the trial per protocol~16. Use of hip protectors~17. With implant or prosthesis on the contralateral hip joint

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aclasta (Type: EXPERIMENTAL): Aclasta IV once annual for 2 years
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete